Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...

AbbVie Inc. closed $6.44 short of its 52-week high ($199.95), which the company achieved on September 3rd.

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

AbbVie Inc (NYSE:ABBV) released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in ...

AbbVie has revealed positive data from a post-hoc analysis of Phase III trials of RINVOQ in treating atopic dermatitis (AD).

According to the last reported balance sheet, AbbVie had liabilities of US$41.9b due within 12 months, and liabilities of ...

Abbvie Inc. failed to defeat a proposed class action by a Chicago-area technician who says he and other workers were ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $193.51 which represents a decrease of $-0.32 or -0.17% from the prior close of $193.83. The stock opened at $192.95 and touched a low of $191.

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other big name stocks. In early April 2024, Goldman Sachs Inc.’s data revealed that short selling ...